Wels WS - Search Results

1

Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.

Rohrbach F, Weth R, Kursar M, Sloots A, Mittrücker HW, Wels WS. Rohrbach F, et al. Among authors: wels ws. J Immunol. 2005 May 1;174(9):5481-9. doi: 10.4049/jimmunol.174.9.5481. J Immunol. 2005. PMID: 15843546

2

Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene.

Gerstmayer B, Altenschmidt U, Hoffmann M, Wels W. Gerstmayer B, et al. J Immunol. 1997 May 15;158(10):4584-90. J Immunol. 1997. PMID: 9144470

3

DNA-carrier proteins for targeted gene delivery.

Uherek C, Wels W. Uherek C, et al. Adv Drug Deliv Rev. 2000 Nov 15;44(2-3):153-66. doi: 10.1016/s0169-409x(00)00092-2. Adv Drug Deliv Rev. 2000. PMID: 11072112 Review.

4

Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.

Rohrbach F, Gerstmayer B, Biburger M, Wels W. Rohrbach F, et al. Clin Cancer Res. 2000 Nov;6(11):4314-22. Clin Cancer Res. 2000. PMID: 11106249

5

Chimeric antigen receptors for the retargeting of cytotoxic effector cells.

Uherek C, Groner B, Wels W. Uherek C, et al. J Hematother Stem Cell Res. 2001 Aug;10(4):523-34. doi: 10.1089/15258160152509136. J Hematother Stem Cell Res. 2001. PMID: 11522235 Review.

6

Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W. Uherek C, et al. Blood. 2002 Aug 15;100(4):1265-73. Blood. 2002. PMID: 12149207 Free article.

7

Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin A translocation domain to target gene transfer to human cancer cells.

Erlwein O, Wels W, Schnierle BS. Erlwein O, et al. Virology. 2002 Oct 25;302(2):333-41. doi: 10.1006/viro.2002.1517. Virology. 2002. PMID: 12441077 Free article.

8

Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors.

Wels W, Biburger M, Müller T, Dälken B, Giesübel U, Tonn T, Uherek C. Wels W, et al. Cancer Immunol Immunother. 2004 Mar;53(3):217-26. doi: 10.1007/s00262-003-0482-8. Epub 2003 Dec 24. Cancer Immunol Immunother. 2004. PMID: 14704833 Free PMC article. Review.

9

A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.

Biburger M, Weth R, Wels WS. Biburger M, et al. Among authors: wels ws. J Mol Biol. 2005 Mar 11;346(5):1299-311. doi: 10.1016/j.jmb.2004.12.052. Epub 2005 Jan 22. J Mol Biol. 2005. PMID: 15713482

10

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.

Roth A, Rohrbach F, Weth R, Frisch B, Schuber F, Wels WS. Roth A, et al. Among authors: wels ws. Br J Cancer. 2005 Apr 25;92(8):1421-9. doi: 10.1038/sj.bjc.6602526. Br J Cancer. 2005. PMID: 15812545 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters